Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

263 enrolled

Breast

Breast Neoplasms

NCT05896566 2026-02-24

PREcoopERA

Phase 2 Completed

231 enrolled

Breast

Breast Neoplasms

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

354 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Phase 3 Active not recruiting

493 enrolled 23 charts 1 FDA

Breast

Breast Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT05514054 2026-01-29

EMBER-4

Phase 3 Active not recruiting

8,000 enrolled

Breast

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

198 enrolled

Breast

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Phase 1 Active not recruiting

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

1,473 enrolled

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

1,903 enrolled

Breast

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2 Active not recruiting

90 enrolled

Breast

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Active not recruiting

8 enrolled

Breast

Breast Neoplasms

Clinical Trials

TAILORx

MNEMOSYNE

ELEGANCE

OPERA-01

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

DEBRA

PIKASSO-01

PIKALO-1

MECCA

PREcoopERA

POWER II

IMPULSE

e3

MONARCH plus

MONARCH 3

Roll-over Study to Allow Continued Access to Ribociclib

EMBER-4

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer